Unlock instant, AI-driven research and patent intelligence for your innovation.

Biodegradable amphiphilic polymers, polymer vesicles prepared therefrom and their application in the preparation of drugs for targeted therapy of lung cancer

A polymer and amphiphilic technology, applied in the field of biodegradable polymer materials, can solve the problems of lack of nano-carriers of hydrophilic small-molecule anticancer drugs, and high-efficiency nano-drugs with low toxicity and side effects, so as to overcome the instability of internal circulation , the effect of simplifying the operation steps

Active Publication Date: 2019-07-12
BRIGHTGENE BIO MEDICAL TECH (SUZHOU) CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the prior art, there is still a lack of high-efficiency nano-drugs with stable circulation in the body, specific targeting of lung cancer, rapid release of drugs in cells, and low toxicity and side effects, especially the lack of nano-carriers that can transport hydrophilic small-molecule anti-cancer drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biodegradable amphiphilic polymers, polymer vesicles prepared therefrom and their application in the preparation of drugs for targeted therapy of lung cancer
  • Biodegradable amphiphilic polymers, polymer vesicles prepared therefrom and their application in the preparation of drugs for targeted therapy of lung cancer
  • Biodegradable amphiphilic polymers, polymer vesicles prepared therefrom and their application in the preparation of drugs for targeted therapy of lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1 Synthesis of cyclic carbonate monomer (CDC) containing disulfide five-membered ring functional group

[0056] Sodium hydrosulfide monohydrate (28.25 g, 381.7 mmol) was dissolved in 400 mL N,N-dimethylformamide (DMF), heated at 50°C until completely dissolved, and dibromoneopentyl glycol (20 g, 76.4 mmol), reacted for 48 hours. The reactant was evaporated under reduced pressure to remove the solvent DMF, then diluted with 200 mL of distilled water, extracted four times with 250 mL of ethyl acetate, and finally the organic phase was rotary evaporated to obtain yellow viscous compound A, yield: 70%; dissolved in 400 mL of tetrahydrofuran Compound A in (THF) was placed in the air for 24 hours, and the intermolecular thiols were oxidized into sulfur-sulfur bonds to obtain compound B with a yield of >98%. Under nitrogen protection, compound B (11.7 g, 70.5 mmol) was dissolved in In dry THF (150 mL), stir until completely dissolved. Following cooling to 0 °C, ethyl...

Embodiment 2

[0057] Example 2 Two-block side chain containing disulfide five-membered ring polymer PEG5k-P (CDC4.9k- co - Synthesis of TMC19k)

[0058] Under a nitrogen atmosphere, 0.1 g (0.52 mmol) of CDC monomer and 0.4 g (3.85 mmol) of trimethylene carbonate (TMC) were dissolved in 3 mL of dichloromethane and added to a sealed reactor, followed by 0.1 g ( 0.02 mmol) CH 3 O-PEG5000 and 0.5 mL catalyst bis(bistrimethylsilyl)amine zinc dichloromethane solution (0.1 mol / L), then seal the reactor well, transfer it out of the glove box, and react in an oil bath at 40 °C for 2 Two days later, the reaction was terminated with glacial acetic acid, precipitated in glacial ether, and finally filtered and vacuum-dried to obtain PEG5k-P (CDC4.9k-co-TMC19.0k). The NMR picture is attached figure 1 , 1 H NMR (400 MHz, CDCl 3 ): 2.08 (t, -COCH 2 CH 2 CH 2 O-), 3.08 (s, -CCH 2 ), 3.30 (m, -OCH 3 ), 3.65 (t, -O CH 2 CH 2 O-), 4.28 (t, -COCH 2 CH 2 CH 2 O-), 4.31 (m, -CCH 2 ). Acco...

Embodiment 3

[0060] Example 3 Two-block side chain containing disulfide five-membered ring polymer Mal-PEG6k-P (CDC4.8k- co - Synthesis of TMC19.2k)

[0061] Under nitrogen atmosphere, 0.1 g (0.52 mmol) of CDC monomer and 0.4 g (3.85 mmol) of TMC were dissolved in 3 mL of dichloromethane and added to the sealed reactor, then 0.12 g (0.02 mmol) of Mal-PEG6000 and 0.1 mol / L catalyst bis(bistrimethylsilyl)amine zinc in dichloromethane solution (0.1 mol / L), then seal the reactor well, transfer it out of the glove box, react in an oil bath at 40 °C for 2 days, and place on ice Acetic acid terminated the reaction, precipitated in glacial ether, and finally filtered and vacuum-dried to obtain Mal-PEG6k-P (CDC4.8k-co-TMC19.2k). 1 H NMR (400 MHz, CDCl 3 ): 2.08 (t, -COCH 2 CH 2 CH 2 O-), 3.08 (s, -CCH 2 ), 3.30 (m, -OCH 3 ), 3.65 (t, -O CH 2 CH 2 O-), 4.28 (t, -COCH 2 CH 2 CH 2 O-), 4.31 (m, -CCH 2 ), and 6.70 (s, Mal). In the following formula calculated by NMR, k=136, x=25, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a biodegradable amphiphilic polymer containing disulfide in the side chain, its self-crosslinked polymer vesicle and its application in targeted therapy of lung cancer. The polymer is obtained through active controllable ring-opening polymerization based on a cyclic carbonate monomer containing a disulfide five-membered ring functional group, and its molecular weight is controllable, its molecular weight distribution is narrow, and no protection and deprotection processes are required; The polymer obtained by the ring-opening polymerization of the cyclocarbonate monomer is biodegradable and can be used in a controlled drug release system. The prepared lung cancer-targeted reduction-sensitive and reversibly cross-linked vesicle nano-drug carrier supports stable long-term circulation in vivo. However, it is highly enriched in lung cancer tissues and efficiently enters cells, rapidly decrosslinks in cells, releases drugs, efficiently and specifically kills cancer cells, and effectively inhibits tumor growth without causing toxic side effects.

Description

technical field [0001] The invention relates to a biodegradable polymer material and its application, in particular to a biodegradable amphiphilic polymer and polymer vesicles with a side chain containing a disulfide five-membered ring functional group and its use in the targeted therapy of lung cancer The application belongs to the field of medical materials. Background technique [0002] Biodegradable polymers have very unique properties and are widely used in various fields of biomedicine, such as surgical sutures, bone fixation devices, biotissue engineering scaffold materials, and drug controlled release carriers. Synthetic biodegradable polymers mainly include aliphatic polyester (polyglycolide PGA, polylactide PLA, lactide-glycolide copolymer PLGA, polycaprolactone PCL), polycarbonate (polytrimethylene Cyclocarbonate PTMC) etc. are the most commonly used biodegradable polymers, which have been approved by the US Food and Drug Administration (FDA). [0003] However, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C08G64/18C08G64/30A61K9/127A61K47/34A61P35/00
CPCA61K9/1273A61K47/34C08G64/183C08G64/30C08G64/025C08G64/081A61K31/337A61K31/704A61K47/62A61K47/6935A61P35/00C08G64/305A61K31/4745A61K31/136C08G64/0241A61K47/6835B82Y5/00C08G2230/00
Inventor 孟凤华邹艳方媛钟志远
Owner BRIGHTGENE BIO MEDICAL TECH (SUZHOU) CO LTD